YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS

Lenvatinib is the latest and promising agent that has demonstrated a significant improvement of progression-free survival in advanced hepatocellular carcinoma (HCC). However, resistance emerges soon after initial treatment, limiting the clinical benefits of lenvatinib. Therefore, understanding the m...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Jun, Zhu, Peng, Ye, Zhi, Wang, Mengke, Yang, Haijun, Huang, Shiqiong, Shu, Yan, Zhang, Wei, Zhou, Honghao, Li, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517968/
https://www.ncbi.nlm.nih.gov/pubmed/34658879
http://dx.doi.org/10.3389/fphar.2021.744578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517968/
https://www.ncbi.nlm.nih.gov/pubmed/34658879
http://dx.doi.org/10.3389/fphar.2021.744578

Ejemplares similares